34. TREATMENT RESULTS OF PEDIATRIC PATIENTS WITH PNEUMONIA USING VANCOMYCIN AND SOME RELATED FACTORS AT NGHE AN OBSTETRICS AND PEDIATRICS HOSPITAL
Main Article Content
Abstract
Objective: To review the treatment results of pediatric pneumonia patients using vancomycin and
find out some its related factors.
Subjects and methods: Descriptive study of 129 pediatric patients were diagnosed with pneumonia
using treatment vancomycin at the Obstetrics and Pediatrics Hospital from April 2023 to March 2014.
Results: The percentage of patients cured and improved after treatment was high, accounted for
58.9% and 28.7%, respectively. The death rate was low (1.6%). The median treatment period was 14
days. The mean initial maintenance vancomycin dose was 59.5 ± 2.3 mg/kg/day with dosing intervals
every 8 hours in most pediatric patients in the study (89.9%). The median duration of vancomycin
treatment was 10 (7-13) days. The rate of achieving the AUC target (400 - 600 mg.h/L) in the first
dosing was 67.4%. Adverse events during vancomycin infusion accounted for 10.3%. Factors
associated with an increased risk of subtherapeutic AUC at first measurement include: age > 24
months, increased renal clearance, and shock.
Conclusion: It is necessary to optimize the initial dose of vancomycin in the population of
pneumonia pediatric patients using vancomycin based on monitoring blood drug concentrations
according to AUC taking into account factors such as age, renal clearance, and shock.
Article Details
Keywords
Pneumonia, vancomycin, trough concentration, area under the curve.
References
associated with acute respiratory infection in
children under the age of 5 years: evidence from the
2011 Ethiopia Demographic and Health Survey.
Pediatric Health, Medicine and Therapeutics.
2015;6:9. doi:10.2147/PHMT.S77915
[2] Rybak MJ, Le J, Lodise TP et al., Therapeutic
monitoring of vancomycin for serious
methicillin-resistant Staphylococcus aureus
infections: A revised consensus guideline and
review by the American Society of HealthSystem Pharmacists, the Infectious Diseases
Society of America, the Pediatric Infectious
Diseases Society, and the Society of Infectious
Diseases Pharmacists. Am J Health Syst Pharm.
2020;77(11):835-864. doi:10.1093/ajhp/zxaa036
[3] Kidney Disease Improving Global Outcomes
(KDIGO), Summary of Recommendation
Statements. Kidney International Supplements.
2012;2(1):8-12. doi:10.1038/kisup.2012.7
[4] Schwartz GJ, Work DF, Measurement and
estimation of GFR in children and adolescents.
Clin J Am Soc Nephrol. 2009;4(11):1832-1843.
doi:10.2215/CJN.01640309
[5] Phạm Anh Tuân, Phân tích tình hình sử dụng
kháng sinh điều trị viêm phổi mắc phải cộng đồng
cho trẻ em tại Bệnh viện Sản Nhi tỉnh Quảng
Ninh. Luận văn Dược sỹ chuyên khoa cấp 1,
Trường Đại học Dược Hà Nội, 2019
[6] Trịnh Thị Vân Anh, Triển khai hiệu chỉnh liều
vancomycin thông qua giám sát nồng độ thuốc
trong máu theo ước đoán Bayesian tại khoa Nhi
Bệnh viện Bạch Mai. Luận văn thạc sỹ Dược học,
Trường Đại học Dược Hà Nội, 2022
[7] Le J, Bradley JS, Murray W et al., Improved
vancomycin dosing in children using area under the
curve exposure. Pediatr Infect Dis J. 2013;32(4):e155-
e163. doi:10.1097/INF.0b013e318286378e
[8] Park SJ, Lim NR, Park HJ et al., Evaluation of risk
factors for vancomycin-induced nephrotoxicity.
Int J Clin Pharm. 2018;40(5):1328-1334.
doi:10.1007/s11096-018-0634-8
[9] Kondo M, Nakagawa S, Orii S et al., Association of
Initial Trough Concentrations of Vancomycin with
Outcomes in Pediatric Patients with Gram-Positive
Bacterial Infection. Biol Pharm Bull. 2020;43(10):
1463-1468. doi:10.1248/bpb.b19-01003